Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies

Albert C. Chen, Ilenia Migliaccio, Mothaffar Rimawi, Sara Lopez-Tarruella, Chad J. Creighton, Suleiman Massarweh, Catherine Huang, Yen Chao Wang, Surinder Kumar Batra, M. Carolina Gutierrez, C. Kent Osborne, Rachel Schiff

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We studied resistance to endocrine and HER2-targeted therapies using a xenograft model of estrogen receptor positive (ER)/HER2-overexpressing breast cancer. Here, we report a novel phenotype of drug resistance in this model. MCF7/HER2-18 xenografts were treated with endocrine therapy alone or in combination with lapatinib and trastuzumab (LT) to inhibit HER2. Archival tumor tissues were stained with hematoxylin and eosin and with mucicarmine. RNA extracted from tumors at early time points and late after acquired resistance were analyzed for mucin4 (MUC4) expression by microarray and quantitative reverse transcriptase-PCR. Protein expression of the MUC4, ER, and HER2 signaling pathways was measured by immunohistochemistry and western blotting. The combination of the potent anti-HER2 regimen LT with either tamoxifen (Tam ? LT) or estrogen deprivation (ED ? LT) can cause complete eradication of ER-positive/HER2-overexpressing tumors in mice. Tumors developing resistance to this combination, as well as those acquiring resistance to endocrine therapy alone, exhibited a distinct histological and molecular phenotype-a striking increase in mucin-filled vacuoles and upregulation of several mucins including MUC4. At the onset of resistance, MUC4 mRNA and protein were increased. These tumors also showed upregulation and reactivation of HER2 signaling, while losing ER protein and the estrogenregulated gene progesterone receptor. Mucins are upregulated in a preclinical model of ER-positive/HER2-overexpressing breast cancer as resistance develops to the combination of endocrine and anti-HER2 therapy. These mucin-rich tumors reactivate the HER2 pathway and shift their molecular phenotype to become more ER-negative/HER2-positive.

Original languageEnglish (US)
Pages (from-to)583-593
Number of pages11
JournalBreast Cancer Research and Treatment
Volume134
Issue number2
DOIs
StatePublished - Jul 1 2012

Fingerprint

Heterografts
Estrogen Receptors
Up-Regulation
Mucins
Breast Neoplasms
Neoplasms
Phenotype
Therapeutics
Progesterone Receptors
Tamoxifen
Hematoxylin
Eosine Yellowish-(YS)
Vacuoles
Reverse Transcriptase Polymerase Chain Reaction
Drug Resistance
Estrogens
Proteins
Western Blotting
Immunohistochemistry
RNA

Keywords

  • Breast cancer
  • Drug resistance
  • Endocrine therapy
  • HER2 therapy
  • Mucin4
  • Mucinated phenotype
  • Mucins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. / Chen, Albert C.; Migliaccio, Ilenia; Rimawi, Mothaffar; Lopez-Tarruella, Sara; Creighton, Chad J.; Massarweh, Suleiman; Huang, Catherine; Wang, Yen Chao; Batra, Surinder Kumar; Gutierrez, M. Carolina; Kent Osborne, C.; Schiff, Rachel.

In: Breast Cancer Research and Treatment, Vol. 134, No. 2, 01.07.2012, p. 583-593.

Research output: Contribution to journalArticle

Chen, AC, Migliaccio, I, Rimawi, M, Lopez-Tarruella, S, Creighton, CJ, Massarweh, S, Huang, C, Wang, YC, Batra, SK, Gutierrez, MC, Kent Osborne, C & Schiff, R 2012, 'Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies', Breast Cancer Research and Treatment, vol. 134, no. 2, pp. 583-593. https://doi.org/10.1007/s10549-012-2082-9
Chen, Albert C. ; Migliaccio, Ilenia ; Rimawi, Mothaffar ; Lopez-Tarruella, Sara ; Creighton, Chad J. ; Massarweh, Suleiman ; Huang, Catherine ; Wang, Yen Chao ; Batra, Surinder Kumar ; Gutierrez, M. Carolina ; Kent Osborne, C. ; Schiff, Rachel. / Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. In: Breast Cancer Research and Treatment. 2012 ; Vol. 134, No. 2. pp. 583-593.
@article{5932021eb9de448ebed978974c8bf0fe,
title = "Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies",
abstract = "We studied resistance to endocrine and HER2-targeted therapies using a xenograft model of estrogen receptor positive (ER)/HER2-overexpressing breast cancer. Here, we report a novel phenotype of drug resistance in this model. MCF7/HER2-18 xenografts were treated with endocrine therapy alone or in combination with lapatinib and trastuzumab (LT) to inhibit HER2. Archival tumor tissues were stained with hematoxylin and eosin and with mucicarmine. RNA extracted from tumors at early time points and late after acquired resistance were analyzed for mucin4 (MUC4) expression by microarray and quantitative reverse transcriptase-PCR. Protein expression of the MUC4, ER, and HER2 signaling pathways was measured by immunohistochemistry and western blotting. The combination of the potent anti-HER2 regimen LT with either tamoxifen (Tam ? LT) or estrogen deprivation (ED ? LT) can cause complete eradication of ER-positive/HER2-overexpressing tumors in mice. Tumors developing resistance to this combination, as well as those acquiring resistance to endocrine therapy alone, exhibited a distinct histological and molecular phenotype-a striking increase in mucin-filled vacuoles and upregulation of several mucins including MUC4. At the onset of resistance, MUC4 mRNA and protein were increased. These tumors also showed upregulation and reactivation of HER2 signaling, while losing ER protein and the estrogenregulated gene progesterone receptor. Mucins are upregulated in a preclinical model of ER-positive/HER2-overexpressing breast cancer as resistance develops to the combination of endocrine and anti-HER2 therapy. These mucin-rich tumors reactivate the HER2 pathway and shift their molecular phenotype to become more ER-negative/HER2-positive.",
keywords = "Breast cancer, Drug resistance, Endocrine therapy, HER2 therapy, Mucin4, Mucinated phenotype, Mucins",
author = "Chen, {Albert C.} and Ilenia Migliaccio and Mothaffar Rimawi and Sara Lopez-Tarruella and Creighton, {Chad J.} and Suleiman Massarweh and Catherine Huang and Wang, {Yen Chao} and Batra, {Surinder Kumar} and Gutierrez, {M. Carolina} and {Kent Osborne}, C. and Rachel Schiff",
year = "2012",
month = "7",
day = "1",
doi = "10.1007/s10549-012-2082-9",
language = "English (US)",
volume = "134",
pages = "583--593",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies

AU - Chen, Albert C.

AU - Migliaccio, Ilenia

AU - Rimawi, Mothaffar

AU - Lopez-Tarruella, Sara

AU - Creighton, Chad J.

AU - Massarweh, Suleiman

AU - Huang, Catherine

AU - Wang, Yen Chao

AU - Batra, Surinder Kumar

AU - Gutierrez, M. Carolina

AU - Kent Osborne, C.

AU - Schiff, Rachel

PY - 2012/7/1

Y1 - 2012/7/1

N2 - We studied resistance to endocrine and HER2-targeted therapies using a xenograft model of estrogen receptor positive (ER)/HER2-overexpressing breast cancer. Here, we report a novel phenotype of drug resistance in this model. MCF7/HER2-18 xenografts were treated with endocrine therapy alone or in combination with lapatinib and trastuzumab (LT) to inhibit HER2. Archival tumor tissues were stained with hematoxylin and eosin and with mucicarmine. RNA extracted from tumors at early time points and late after acquired resistance were analyzed for mucin4 (MUC4) expression by microarray and quantitative reverse transcriptase-PCR. Protein expression of the MUC4, ER, and HER2 signaling pathways was measured by immunohistochemistry and western blotting. The combination of the potent anti-HER2 regimen LT with either tamoxifen (Tam ? LT) or estrogen deprivation (ED ? LT) can cause complete eradication of ER-positive/HER2-overexpressing tumors in mice. Tumors developing resistance to this combination, as well as those acquiring resistance to endocrine therapy alone, exhibited a distinct histological and molecular phenotype-a striking increase in mucin-filled vacuoles and upregulation of several mucins including MUC4. At the onset of resistance, MUC4 mRNA and protein were increased. These tumors also showed upregulation and reactivation of HER2 signaling, while losing ER protein and the estrogenregulated gene progesterone receptor. Mucins are upregulated in a preclinical model of ER-positive/HER2-overexpressing breast cancer as resistance develops to the combination of endocrine and anti-HER2 therapy. These mucin-rich tumors reactivate the HER2 pathway and shift their molecular phenotype to become more ER-negative/HER2-positive.

AB - We studied resistance to endocrine and HER2-targeted therapies using a xenograft model of estrogen receptor positive (ER)/HER2-overexpressing breast cancer. Here, we report a novel phenotype of drug resistance in this model. MCF7/HER2-18 xenografts were treated with endocrine therapy alone or in combination with lapatinib and trastuzumab (LT) to inhibit HER2. Archival tumor tissues were stained with hematoxylin and eosin and with mucicarmine. RNA extracted from tumors at early time points and late after acquired resistance were analyzed for mucin4 (MUC4) expression by microarray and quantitative reverse transcriptase-PCR. Protein expression of the MUC4, ER, and HER2 signaling pathways was measured by immunohistochemistry and western blotting. The combination of the potent anti-HER2 regimen LT with either tamoxifen (Tam ? LT) or estrogen deprivation (ED ? LT) can cause complete eradication of ER-positive/HER2-overexpressing tumors in mice. Tumors developing resistance to this combination, as well as those acquiring resistance to endocrine therapy alone, exhibited a distinct histological and molecular phenotype-a striking increase in mucin-filled vacuoles and upregulation of several mucins including MUC4. At the onset of resistance, MUC4 mRNA and protein were increased. These tumors also showed upregulation and reactivation of HER2 signaling, while losing ER protein and the estrogenregulated gene progesterone receptor. Mucins are upregulated in a preclinical model of ER-positive/HER2-overexpressing breast cancer as resistance develops to the combination of endocrine and anti-HER2 therapy. These mucin-rich tumors reactivate the HER2 pathway and shift their molecular phenotype to become more ER-negative/HER2-positive.

KW - Breast cancer

KW - Drug resistance

KW - Endocrine therapy

KW - HER2 therapy

KW - Mucin4

KW - Mucinated phenotype

KW - Mucins

UR - http://www.scopus.com/inward/record.url?scp=84868206699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868206699&partnerID=8YFLogxK

U2 - 10.1007/s10549-012-2082-9

DO - 10.1007/s10549-012-2082-9

M3 - Article

VL - 134

SP - 583

EP - 593

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -